SELDI-TOF serum proteomics and colorectal cancer: A current overview

Archives of Physiology and Biochemistry

Volumn 116, Issue 4-5, 2010, Pages 188-196

  Gemoll, Timo ^a,b   Roblick, Uwe Johannes ^a,b   Auer, Gert ^b   Jörnvall, Hans ^b   Habermann, Jens Karsten ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarker; Colon cancer; Serum; Validation

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; TUMOR PROTEIN;

BLOOD; CHEMISTRY; COLORECTAL TUMOR; HUMAN; MASS SPECTROMETRY; METHODOLOGY; PROTEIN MICROARRAY; PROTEOMICS; REPRODUCIBILITY; REVIEW; SECRETION; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BLOOD PROTEINS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78649270438     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2010.495130     Document Type: Review

References (28)

1. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. (2005). Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5:8.
2. Anderson NL, Anderson, NG. (2002). Te human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845-67.
3. Bons JA, De Boer D, van Dieijen-Visser MP, Wodzig WK. (2006). Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of fight-mass spectrometry. Clin Chim Acta 366:249-56.
4. Chen YD, Zheng S, Yu JK, Hu X. (2004). Artifcial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10:8380-85.
5. Engwegen JY, Depla AC, Smits ME, Cats A, Tuynman H, van Heukelem HA, Snel P, Meuleman W, Wessels LF, Schellens, et al. (2008). Detection of colorectal cancer by serum and tissue protein profling: A prospective study in a population at risk. Biomark Insights 3:375-85.
6. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. (2006a). Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 27:251-9.
7. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schelens JH, Beijnen JH. (2006b). Identifcation of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of fight mass spectrometry. World J Gastroenterol 12:1536-44.
8. Fuchs B, Schiller J. (2008). MALDI-TOF MS analysis of lipids from cells, tissues and body fuids. Subcell Biochem 49:541-65.
9. Gast MC, Schellens JH, Beijnen JH. (2009). Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17-29.
10. Habermann JK, Bader FG, Franke C, Zimmermann K, Gemoll T, Fritzsche B, Ried T, Auer G, Bruch HP, Roblick UJ. (2008). From the genome to the proteome-biomarkers in colorectal cancer. Langenbecks Arch Surg 393:93-104.
11. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, Roman JM, Oevermann E, Schiedeck T, Homann N, et al. (2006). Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131:1020-9; quiz 1284.
12. Ikonomou G, Samiotaki M, Panayotou, G. (2009). Proteomic methodologies and their application in colorectal cancer research. Crit Rev Clin Lab Sci 46:319-42.
13. Liu M, Li CF, Chen HS, Lin LQ, Zhang CP, Zhao JL, Liu Y, Zhang SJ, Jin JC, Wang L, et al. (2010). Diferential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci 8:16.
14. Liu XP, Shen J, Li ZF, Yan L, Gu J. (2006). A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 24:747-53.
15. Mallow EB, Harris A, Salzman N, Russell JP, Deberardinis R, Ruchelli E, Bevins CL. (1996). Human enteric defensins. Gene structure and development expression. J Biol Chem 271:4038-45.
16. Mannello F, Medda V, Tonti GA. (2009). Protein profle analysis of the breast microenvironment to diferentiate healthy women from breast cancer patients. Expert Rev Proteomics 6:43-60.
17. Melle C, Ernst G, Schimmel B, Bleul A, Tieme H, Kaufmann R, Mothes H, Settmacher U, Claussen U, Halbhuber KJ, et al. (2005). Discovery and identifcation of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 129:66-73.
18. O'Farrell PH. (1975). High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007-21.
19. Pandey A, Mann M. (2000). Proteomics to study genes and genomes. Nature 405:837-46.
20. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
21. Poon TPW. (2007). Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 4:51-65.
22. Qian WJ, Jacobs JM, Liu T, Camp 2nd DG, Smith RD. (2006). Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profling for clinical applications. Mol Cell Proteomics 5:1727-44.
23. Reddy G, Dalmasso EA. (2003). SELDI Protein Chip (R) array technology: Protein-based predictive medicine and drug discovery applications. J Biomed Biotechnol 2003:237-41.
24. Seibert V, Wiesner A, Buschmann T, Meue, J. (2004). Surfaceenhanced laser desorption ionization time-of-fight mass spectrometry (SELDI TOF-MS) and Protein Chip technology in proteomics research. Pathol Res Pract 200:83-94.
25. Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu, J. (2009). Limitations in SELDI-TOF MS whole serum proteomic profling with IMAC surface to specifcally detect colorectal cancer. BMC Cancer 9:287.
26. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. (2006). Identifcation of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94:1898-905.
27. Zheng GX, Wang CX, Qu X, Deng XM, Deng BP, Zhang J. (2006). Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol 28:282-7.
28. Zieske LR. (2006). A perspective on the use of iTRAQ reagent technology for protein complex and profling studies. J Exp Bot 57:1501-8.